Genomic Signatures Predict the Immunogenicity of BRCA-deficient Breast Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-0468
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phase 1 Trial of Olaparib and Oral Cyclophosphamide in BRCA Breast Cancer, Recurrent BRCA Ovarian Cancer, Non-Brca Triple-Negative Breast Cancer, and Non-Brca Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

BRCA Mutations in Women With Inflammatory Breast Cancer

Cancer
Cancer ResearchOncology
2017English

High-Throughput Genomic Technology in Research and Clinical Management of Breast Cancer. Molecular Signatures of Progression From Benign Epithelium to Metastatic Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2006English

Serum Proteomic Signatures of Male Breast Cancer

Cancer Genomics and Proteomics
MedicineBiochemistryGeneticsMolecular BiologyCancer Research
2019English

The Genomic Signature of Breast Cancer Prevention

English

The Value of BRCA 1 Gene Mutation in Patients With Breast Cancer

Sohag Medical Journal
2018English

Clinical and Molecular Characterization of BRCA-associated Breast Cancer: Results From the DBCG

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2017English

Functional Genomic Approaches to Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2005English

Novel Immunohistochemistry-Based Signatures to Predict Metastatic Site of Triple-Negative Breast Cancers

British Journal of Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy